bcl-2, bax, bcl-x(L), and bcl-x(S) expression in normal and neoplastic ovarian tissues

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 517-524

  Marone, Maria ^a   Scambia, Giovanni ^a   Mozzetti, Simona ^a   Ferrandina, Gabriella ^a   Iacovella, Sonia ^a   De Pasqua, Anna ^a   Benedetti Panici, Pierluigi ^a   Mancuso, Salvatore ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL DEATH; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; TUMOR GROWTH;

BCL-X PROTEIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS C-BCL-2; REFERENCE VALUES; RNA; RNA, NEOPLASM;

EID: 0031939573     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science, 267: 1456-1462, 1995.
2. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
3. Hickman, J. A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
4. Hockenbery, D. M., Nuñez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334-336, 1990.
5. Nuñez, G., London, L., Hockenbery, D., Alexander, G. M., and McKearn, J. P. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol., 144: 3602-3610, 1990.
6. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood, 81: 151-157, 1993.
7. Yin, X., Oltvai, Z. N., and Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Cell, 74: 607-619, 1993.
8. Rao, L., and White, E. Bcl-2 and the ICE family of apoptotic regulators: making a connection. Curr. Opin. Genet. Dev., 7: 52-58, 1997.
9. Sedlak, T. W., Oltvai, Z. N., Yang, E., Wang, K., Boise, L. H., Thompson, C. B., and Korsmeyer, S. J. Multiple Bcl-2 family members demonstrate selective dimerization with Bax. Proc. Natl. Acad. Sci. USA, 92: 7834-7838, 1995.
10. Sato, T., Hanada, M., Bodrug, S., Irie, S., Iwama, N., Boise, L. H., Thompson, C.B., Golemis, E., Fong, L., Wang, H., and Reed, J. C., Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. USA, 91: 9238-9242, 1994.
11. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J., Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
12. Yin, C., Knudson, C. M., Korsmeyer, S. J., and Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature (Lond.), 385: 637-640, 1997.
13. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G., and Thompson, C. B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
14. Linette, G. P., Li, Y., Roth, K., and Korsmeyer, S. J. Cross talk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. Proc. Natl. Acad. Sci. USA, 93: 9545-9552, 1996.
15. ++ pool depletion. Oncogene, 72: 2051-2055, 1996.
16. Cerroni, L., Soyer, H. P., and Kerl, H. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermopathol., 17: 7-11, 1995.
17. Pezzella, F., Turley, H., Kuzu, I., Tungekar, M. F., Dunnill, M. S., Pierce, C. B., Harris, A., Gatter, K. C., and Mason, D. Y. bcl-2 protein expression in non-small-cell lung carcinoma. N. Engl. J. Med., 329: 690-694, 1993.
18. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J., Tu, S., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
19. Silvestrini, R., Veneroni, S., Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F., and Veronesi, U. The Bcl-2 protein, a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. (Bethesda), 86: 499-504, 1994.
20. Krajewski, S., Bodrug, S., Gascoyne, R., Berean, K., Krajewska, M., and Reed, J. C. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am. J. Pathol., 145: 515-525, 1994.
21. Ceccarelli, C., Santini, D., Chieco, P., Taffurelli, M., Marrano, D., and Mancini, A. M. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. Ann. Oncol., 6: 275-282, 1995.
22. Sierra, A., Lloveras, B., Castellsagué, X., Moreno, L., Garcia-Ramirez, M., and Fabra, A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int. J. Cancer, 60: 54-60, 1995.
23. Hellemans, P., van Dam, P. A., Weyler, J., van Oosterom, A. T., Buytaert, P., and van Marck, E. Prognostic value of bcl-2 expression in invasive breast cancer. Br. J. Cancer, 72: 354-360, 1995.
24. Hurlimann, J., Larrinaga, B., and Vala, D. M. L. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch., 426: 163-168, 1995.
25. Krajewski, S., Blomqvist, C., Franssila, K., Krajewska, M., Wasenius, V. M., Niskanen, E., Nordling, S., and Reed, J. C. Reduced expression of proapoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res., 55: 4471-4478, 1995.
26. Henriksen, R., Wilander, E., and Oberg, K. Expression and prognostic significance of Bcl-2 in ovarian tumors, Br. J. Cancer, 72: 1324-1329, 1995.
27. Herod, J. J., Eliopoulos, A. G., Warwick, J., Niedobitek, G., Young, L. S., and Kerr, D. J. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res., 56: 2178-2184, 1996.
28. WHO. WHO Handbook for Reporting Results of Cancer Treatment, Publication No. 48, p.p. 16-21. Geneva: WHO, 1979.
29. Chomczynsky, P., and Sacchi, N. Single step method of RNA isolation by guanidium-thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
30. Wang, T. T. Y., and Phang, J. M. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res., 55: 2487-2489, 1995.
31. Elledge, R. M., Clark, G. M., Fuqua, S., Yu, Y., and Allred, D. C. p53 protein accumulation detected by five different antibodies: relationship of prognosis and heat shock protein 70 in breast cancer. Cancer Res., 54: 3752-3757, 1994.
32. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptor in human breast cancer. Eur. J. Cancer, 16: 1515-1517, 1980.
33. Krajewska, M., Fenoglio-Preiser, C. M., Krajewski, S., Song, K., Macdonald, J. S., Stemmerman, G., and Reed, J. C. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol., 149: 1449-1457, 1996.
34. Gottschalk, A. R., Boise, L. H., Thompson, C. B., and Quintans, J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. Natl. Acad. Sci. USA, 91: 7350-7354, 1994.
35. L. Nature (Lond.), 374: 811-813, 1995.
36. Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D., and Dorken, B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-α expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer, 60: 854-859, 1995.
37. Krajewska, M., Krajewski, S., Epstein, J. I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S., and Reed, J. C. Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. Am. J. Pathol., 148: 1567-1576, 1996.
38. Eliopoulos, A. G., Kerr, D. J., Herod, J. J. O., Hodgkins, L., Krajewski, S., Reed, J. C., Young, L. S., and Herod, J. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217-1228, 1995.
39. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56: 556-562, 1996.
40. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C., Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
41. Diebold, J., Baretton, G., Felchner, M., Meier, W., Dopfer, K., Schmidt, M., and Lohrs, U. bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am. J. Clin. Pathol., 705: 341-349, 1996.
42. Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., McClelland, R. A., Hoyle, H. B., Kyme, S. R., Finlay, P., Blarney, R. W., and Nicholson, R. I., Immunohistochemical localization of bcl-2 protein in human breast cancers and it relationship to a series of prognostic markers and response to chemotherapy. Int. J. Cancer, 59: 619-628, 1994.
43. Gompel, A., Sabourin, J. C., Martin, A., Yaneva, H., Audouin, J., Decroix, Y., and Poitout, P. Bcl-2 expression in normal endometrium during the menstrual cycle. Am. J. Pathol., 6: 1195-1202, 1994.
44. Saegusa, M., Kamata, Y., Isono, M., and Okayasu, I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial cancer. J. Pathol., 180: 275-282, 1996.
45. White, E. Life, death, and the pursuit of apoptosis. Genes Dev., 10: 1-15, 1996.
46. L forms an ion channel in synthetic lipid membranes. Nature (Lond.), 385: 353-357.
47. O'Reilly, L. A., Huang, D. C. S., and Stasser, A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J., 75: 6979-6990, 1996.